AR015252A1 - Moleculas de polinucleotido aisladas, moleculas de oligonucleotido, vector recombinante, celula hospedadora transformada, polipeptido aislado osustancialmente purificado, anticuerpo aislado, construccion genetica, celula de neospora modificada, procedimiento para prepararla, vacuna contra laneosporo - Google Patents

Moleculas de polinucleotido aisladas, moleculas de oligonucleotido, vector recombinante, celula hospedadora transformada, polipeptido aislado osustancialmente purificado, anticuerpo aislado, construccion genetica, celula de neospora modificada, procedimiento para prepararla, vacuna contra laneosporo

Info

Publication number
AR015252A1
AR015252A1 ARP990101308A ARP990101308A AR015252A1 AR 015252 A1 AR015252 A1 AR 015252A1 AR P990101308 A ARP990101308 A AR P990101308A AR P990101308 A ARP990101308 A AR P990101308A AR 015252 A1 AR015252 A1 AR 015252A1
Authority
AR
Argentina
Prior art keywords
molecules
cell
antibody
isolated
transformed
Prior art date
Application number
ARP990101308A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR015252A1 publication Critical patent/AR015252A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Abstract

La presente proporciona moléculas de polinucleotido aisladas que comprenden secuencias de nucleotidos que codifican las proteínas GRA1, GRA2, SAG1, MIC1 yMAG1 de Neospora caninum, así como vectores recombinantes, células hospedadoras transformadas yproteínas expresadas de forma recombinante. La presente ademásproporciona una molécula de polinucleotido que comprende la secuencia de nucleotidos del promotor bidireccional GRA1/MAG1 de N. caninum. La presente ademásproporciona construcciones genéticas basadas en las moléculas de polinucleotido de la presente invencion que son utiles en la preparacion de cepas modificadasde células de Neospora para uso en vacunas contra la neosporosis. También se proporcionan polipéptidos aislados o sustancialmente purificados, métodos parapreparar células de Neospora modificadas, moleculas de oligonucleotido, vacuna contra neosporosis; método para prepararla, método para vacunar un mamífero yequipo de vacunacion. También se describen anticuerpos aisladosque reaccionan contra N. caninum.
ARP990101308A 1998-03-26 1999-03-24 Moleculas de polinucleotido aisladas, moleculas de oligonucleotido, vector recombinante, celula hospedadora transformada, polipeptido aislado osustancialmente purificado, anticuerpo aislado, construccion genetica, celula de neospora modificada, procedimiento para prepararla, vacuna contra laneosporo AR015252A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7938998P 1998-03-26 1998-03-26
US11228298P 1998-12-15 1998-12-15

Publications (1)

Publication Number Publication Date
AR015252A1 true AR015252A1 (es) 2001-04-18

Family

ID=26761953

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990101308A AR015252A1 (es) 1998-03-26 1999-03-24 Moleculas de polinucleotido aisladas, moleculas de oligonucleotido, vector recombinante, celula hospedadora transformada, polipeptido aislado osustancialmente purificado, anticuerpo aislado, construccion genetica, celula de neospora modificada, procedimiento para prepararla, vacuna contra laneosporo

Country Status (9)

Country Link
US (2) US6600027B1 (es)
EP (1) EP0953641A3 (es)
JP (5) JPH11332583A (es)
CN (1) CN1232087A (es)
AR (1) AR015252A1 (es)
AU (1) AU759103B2 (es)
BR (1) BR9902019A (es)
CA (1) CA2264260A1 (es)
NZ (1) NZ334839A (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0953641A3 (en) * 1998-03-26 2002-03-13 Pfizer Products Inc. Polynucleotide molecules encoding neospora proteins
ES2263317B2 (es) * 2003-12-04 2007-10-01 Universidad Complutense De Madrid Uso del gen ncsag4 para el diagnostico y prevencion de la neosporosis, y como marcador para el analisis de la patogenia.
KR101143060B1 (ko) * 2004-04-05 2012-05-08 화이자 프로덕츠 인코포레이티드 미세유체화된 수중유 유화액 및 백신 조성물
ES2319242B1 (es) 2005-12-23 2009-12-01 Laboratorios Hipra, S.A. Aislado avirulento de neospora canimum y sus usos.
ES2326770B1 (es) 2007-07-13 2010-07-26 Universidad Complutense De Madrid Uso de un nuevo aislado de neospora caninum para el desarrollo de pruebas de diagnostico y para la fabricacion de productos para el tratamiento y prevencion de la infenccion causada por neospora.
CN104758929B (zh) * 2008-06-27 2018-05-25 硕腾有限责任公司 新颖的佐剂组合物
CN101831495B (zh) * 2010-04-30 2013-06-19 新疆出入境检验检疫局检验检疫技术中心 一种牛新孢子虫病的检测方法及应用
CA2868391A1 (en) * 2012-04-02 2013-10-10 Stephane Bancel Polynucleotides comprising n1-methyl-pseudouridine and methods for preparing the same
FR2994193B1 (fr) * 2012-08-02 2016-05-20 Vitamfero Souches mutantes de neospora et leurs utilisations
CN102838984B (zh) * 2012-09-12 2014-06-04 浙江理工大学 一种胰凝乳蛋白酶保护金纳米团簇荧光材料的制备方法
CN107325166A (zh) * 2017-05-15 2017-11-07 华中农业大学 柔嫩艾美耳球虫表面抗原基因sag6所编码的重组蛋白及其应用
CN110407944B (zh) * 2018-04-29 2023-04-21 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 隐孢子虫多表位基因片段cpmcef及其融合蛋白和应用
CN110183527B (zh) * 2019-05-21 2021-03-12 中国农业大学 一种新孢子虫NcMIC26抗原及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3940598A1 (de) * 1989-12-08 1991-06-13 Behringwerke Ag Toxoplasma gondii-antigene, ihre herstellung und ihre verwendung
FR2625099B1 (fr) * 1987-12-24 1991-06-14 Transgene Sa Proteines et leur procede de preparation, sequences d'adn, anticorps et leur application, poxvirus, cellules transformees ou infectees et compositions pharmaceutiques utiles dans la prevention de la toxoplasmose
US5665542A (en) * 1989-11-03 1997-09-09 Research Institute Of Palo Alto Medical Foundation Toxoplasma gondii P28 gene and methods for its use
FR2692282B1 (fr) * 1992-06-15 1995-07-13 Pasteur Institut Clonage du gene codant pour la proteine gp28.5 de t. gondii; fragments peptidiques issus de ladite proteine et leurs applications.
US5643718A (en) 1993-11-04 1997-07-01 The Board Of Trustees Of The Leland Stanford Junior University Transfection and genetic manipulations in obligate intracellular parasites
US5976553A (en) 1993-11-04 1999-11-02 The Board Of Trustees Of The Leland Stanford Junior University Transfection and genetic manipulations in obligate intracellular parasites
FR2714074B1 (fr) * 1993-12-20 1996-03-01 Pasteur Institut Promoteurs des gènes GRA1, GRA2, GRA5 et GRA6 de toxoplasma gondii et vecteurs d'expression comprenant lesdits promoteurs.
US5707617A (en) 1994-03-21 1998-01-13 The Regents Of The University Of California Bovine neospora isolates
US5889166A (en) * 1996-05-10 1999-03-30 The Regents Of The University Of California Recombinant neospora antigens and their uses
AU7677896A (en) 1995-11-09 1997-05-29 Trustees Of Dartmouth College A vaccine against toxoplasma gondii
US6476192B1 (en) * 1996-04-15 2002-11-05 Nicola C. Lally Recombinant antigens useful for the serodiagnosis of neosporosis
AUPO188396A0 (en) 1996-08-26 1996-09-19 Insearch Limited Detection of protozoan parasites
PT841392E (pt) * 1996-11-12 2004-11-30 Univ Auburn Vacina viva atenuada de neospora
AUPO690397A0 (en) 1997-05-20 1997-06-12 Insearch Limited Large subunit ribosomal dna of neospora species
BR9803232A (pt) * 1997-08-26 2000-01-11 Pfizer Prod Inc Vaicna de neospora.
ES2281936T3 (es) 1997-10-20 2007-10-01 Bayer Corporation Vacuna contra neospora.
US6071737A (en) 1998-03-16 2000-06-06 The Regents Of The University Of California Equine Neospora isolate and its uses
EP0953641A3 (en) * 1998-03-26 2002-03-13 Pfizer Products Inc. Polynucleotide molecules encoding neospora proteins
AUPP371798A0 (en) 1998-05-26 1998-06-18 Insearch Limited Parasite antigens
US20040131633A1 (en) * 1999-04-21 2004-07-08 University Of Technology, Sydney Parasite antigens

Also Published As

Publication number Publication date
CN1232087A (zh) 1999-10-20
AU2243799A (en) 1999-10-07
JP2005211081A (ja) 2005-08-11
JP2005245456A (ja) 2005-09-15
JPH11332583A (ja) 1999-12-07
US6600027B1 (en) 2003-07-29
JP2005211082A (ja) 2005-08-11
AU759103B2 (en) 2003-04-03
BR9902019A (pt) 2000-05-02
US20030180785A1 (en) 2003-09-25
EP0953641A3 (en) 2002-03-13
CA2264260A1 (en) 1999-09-26
EP0953641A2 (en) 1999-11-03
NZ334839A (en) 2000-08-25
JP2005253467A (ja) 2005-09-22

Similar Documents

Publication Publication Date Title
AR015252A1 (es) Moleculas de polinucleotido aisladas, moleculas de oligonucleotido, vector recombinante, celula hospedadora transformada, polipeptido aislado osustancialmente purificado, anticuerpo aislado, construccion genetica, celula de neospora modificada, procedimiento para prepararla, vacuna contra laneosporo
ES2545886T3 (es) Inmunoterapia dirigida a patógenos intracelulares
AU2007201553B2 (en) Expression system
ES2662801T3 (es) Vacunas atenuadas contra Streptoccocus suis y procedimientos de fabricación y uso de las mismas
CN103981204B (zh) 一种有活性的金鱼Tgf2转座子重组转座酶蛋白的表达方法
JP2011516070A5 (es)
WO2003106684A3 (en) PROCESS FOR THE SIMULTANEOUS PRODUCTION OF SEVERAL PROTEINS; VECTORS AND CELLS USED IN THIS PROCESS
CN108912221A (zh) 用于生产重组融合蛋白的辅助蛋白、编码基因、重组融合蛋白、重组表达载体及制备方法
ES2398492T3 (es) Proteínas de fusión que comprenden los antígenos de rechazo tumoral NY-ESO-1 y LAGE-1
TW200716166A (en) Lawsonia intracellularis immunological proteins
NZ598605A (en) Vaccine against african horse sickness virus
ES2244993T3 (es) Metodo recombinante para la preparacion de un antigeno completo de malaria gp190/msp1.
WO2006102901A3 (en) Immunogenic egfr peptides comprising foreign t cell stimulating epitope
MXPA04004561A (es) Distribuidor de aire para sistema de biolixiviacion.
EP1412374A4 (en) NEW PGC-1 ISOFORMS AND THEIR USES
US20140322257A1 (en) Fusion proteins representing different ns: proposal for a vaccine against allergy to mites
TW200801034A (en) Novel sea lice vaccine
ZA200602107B (en) Piroplasmid vaccine
EP1233024A3 (en) 25466, a human transporter family member and uses therefor
GB2369618B (en) Live vaccine expressing antigens using phoP or pagC promoters
AR041243A1 (es) Vacuna para ostertagia
AR017709A1 (es) Molecula de polinucleotido aislada, vector recombinante, celula hospedadora recombinante, proteina sustancialmente purificada, polipeptidosustancialmente purificado, fragmento peptidico, anticuerpo, constructo genetico, celula de neospora transformada, procedimiento para modificar celulas deneospora
WO2004056316A3 (en) Vaccines against hiv-1 tat protein to generate neutralizing antibodies
AR040830A1 (es) Vacuna para combatir la infeccion que produce la mastitis
ES2441880A1 (es) Composición basada en polipéptidos para el tratamiento de miasis

Legal Events

Date Code Title Description
FB Suspension of granting procedure